A newly published study found that intravitreal injection of autologous CD34+ stem cells is well tolerated and feasible for treating loss of vision resulting from central retinal vein occlusion (CRVO) ...

Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing ...

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. EYE PCR’s fixOflex is now eligible for European ...

Prolonged near work in low luminance may accelerate myopia primarily by limiting retinal illumination through sustained accommodative miosis rather than by electronic screens per se.

Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, irregular astigmatism, corneal dystrophies, scarring, and diseases of the ...

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, ...

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

In this Q&A article with the Eye Care Network, Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses the role of low- and middle-income country (LMIC) data in informing US ophthalmology clinical trials, ...

At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...